January 9, 2020 - Scientists and technicians working on arbovirus projects in Senegal and West Africa are meeting for a training workshop organized by the Mérieux Foundation and Institut Pasteur of Dakar from January 6-10, 2020. Read more
October 30, 2019 - The Global Birth Defects Description and Coding (GBDDC) app has just been released today. This first of its kind app provides images and definitions of major externally visible birth defects with ICD codes, in addition to ... Read more
October 28, 2019 - The Universidad del Valle hosted the annual ZikaPLAN meeting October 21-22, convening over 60 consortium members in Cali, Colombia. Read more
October 24, 2019 - The toolkit is based on guidelines developed by scientists funded by the EUHorizon2020 grant and the ZikaPLAN-supported IGOSZika project. Read more
October 7, 2019 - Scientists funded by the EU Horizon 2020 grant and the ZikaPLAN-supported IGOS-Zika project have developed a globally applicable guideline for the diagnosis and management of Guillain–Barré syndrome(GBS) as a tool for clinicians. Their paper the "Diagnosis ... Read more
Gaunt M. W. et al. - Antiviral Research, February 2020
This study provides a possible explanation of why explosive ZIKV epidemics occurred in DENV-endemic regions of Micronesia, Polynesia and the Americas where Culex-borne flavivirus outbreaks are infrequent and why ZIKV did not cause major epidemics in Asia where Culex-borne flaviviruses are widespread.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.